Original ResearchFull Report: Clinical—Alimentary TractRadiofrequency Ablation Is Associated With Decreased Neoplastic Progression in Patients With Barrett's Esophagus and Confirmed Low-Grade Dysplasia
Section snippets
Patients and Settings
The source cohort came from 3 referral centers within the Barrett's Esophagus Translational Research Network (BETRNet) consortium funded by the National Cancer Institute: the University of Pennsylvania, Columbia University, and the Mayo Clinic. Within this cohort, BE patients who had a diagnosis of LGD as verified by histopathology from October 1992 (the date of earliest registration of LGD patients available) to December 2013 were identified for study inclusion. The inclusion criteria for this
Patients and Barrett's Characteristics
A total of 170 patients met inclusion criteria: 125 underwent surveillance only and 45 underwent RFA (Figure 1; Supplementary Figure 1). The 2 groups were similar in baseline characteristics, except for higher proton pump inhibitor use in the RFA patients and center differences in the proportion of patients undergoing ablation (Table 1). There were numerically, but not statistically, more visible macroscopic lesions detected in the surveillance group compared with the ablated group (10.4% vs
Discussion
In this multicenter study of patients with confirmed LGD, we observed a high progression rate to HGD or adenocarcinoma in the surveillance group; however, progression rates were much lower with RFA. We estimate that for every 3 patients treated with RFA, 1 additional patient with LGD will avoid progression to HGD or EAC within 3 years. We were not able to demonstrate a significant reduction in EAC, although this was a rare event and, as such, our power to determine a difference was much less
References (45)
- et al.
Consensus Statements for Management of Barrett's Dysplasia and Early-Stage Esophageal Adenocarcinoma, Based on a Delphi Process
Gastroenterology
(2012) - et al.
How to manage a Barrett's esophagus patient with low-grade dysplasia
Clin Gastroenterol Hepatol
(2009) - et al.
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia
Gastroenterology
(2011) - et al.
Radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: a hammer looking for a nail
Gastroenterology
(2014) - et al.
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications
Hum Pathol
(1983) - et al.
Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation
Hum Pathol
(2001) - et al.
The diagnosis of low-grade dysplasia in Barrett's esophagus and its implications for disease progression
Am J Gastroenterol
(2000) - et al.
Esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia
Gastrointest Endosc
(2015) - et al.
Barrett's esophagus: who should receive ablation and how can we get the best results?
Gastroenterology
(2012) - et al.
Quantification of the placebo response in ulcerative colitis
Gastroenterology
(1997)
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial
Gastroenterology
High-grade dysplasia in Barrett’s esophagus: surveillance or operation?
J Gastrointest Surg
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus
Gastroenterology
Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis
Clin Gastroenterol Hepatol
Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma
Gastroenterology
Adherence to biopsy guidelines for Barrett's esophagus surveillance in the community setting in the United States
Clin Gastroenterol Hepatol
Esophageal cancer: associated factors with special reference to the Kashmir Valley
Tumori
Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age
J Natl Cancer Inst
American Gastroenterological Association medical position statement on the management of Barrett's esophagus
Gastroenterology
Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus
Gastroenterology
Low-grade dysplasia in Barrett's esophagus: overdiagnosed and underestimated
Am J Gastroenterol
Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis
Gut
Cited by (0)
This article has an accompanying continuing medical education activity on page e13. Learning Objective: Upon completion of this exercise, successful learners will be able to (a) discuss management of low-grade dysplasia in Barrett's esophagus, (b) identify strategies to reduce the risk of low-grade dysplasia advancing to high-grade dysplasia, and (c) discuss the role of specialized GI pathologists in pathologic review of biopsies diagnosed as low-grade dysplasia by general pathologists.
Conflicts of interest These authors disclose the following: Julian A. Abrams has served as a consultant to C2 Therapeutics. He has received research support from C2 Therapeutics and Covidien. Charles J. Lightdale has served as a consultant to Boston Scientific, C2 Therapeutics, CSA Medical, Mauna Kea Technologies, and NinePoint Medical. He has received royalties from Cook Medical. Prasad G. Iyer has received research support from Takeda Pharmaceuticals. Kenneth K. Wang has received research support from BaRRx, Pinnacle Pharma, and CSA. James D. Lewis has served as a consultant to Takeda, Amgen, Millennium Pharmaceuticals, Pfizer, Abbott, Prometheus, Nestle, Lilly, and Shire. He has received research funding from Shire, Takeda, and Centocor. Gray W. Falk serves as a consultant to CDX and receives research support from CDX. Meenakshi Bewtra has received research support from Janssen and Imedex. The remaining authors disclose no conflicts.
Funding This work was supported by the National Institutes of Health (NIH)/National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) T32 DK007740 (Clinical Epidemiology Training in Gastroenterology), the NIDDK 1 K08 DK084347-01, the NIH K24-DK078228, the NIH/NCI U54-CA163004, the NIH/NIDDK P30DK050306 Center for Molecular Studies in Digestive and Liver Diseases, and the NIH/NCI P01-CA098101 and institutional funds.
Author names in bold designate shared co-first authors.